LYNPARZA Trial for BRCA-Mutated HER2-Negative Breast Cancer Achieved iDFS Superiority Boundary
In a joint statement, biopharmaceutical companies AstraZeneca and Merck & Co., Inc. ("Merck") shared that LYNPARZA (olaparib) achieved a superiority boundary in the Phase 3 OlympiA clinical trial. During…